metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED ...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY
Visits
300
Francisco Idalsoaga1, Luis Antonio Diaz1, Oscar Corsi1, Gustavo Ayares1, Jorge Arnold1, Winston Dunn2, Yanming Li2, Ashwani Singal3, Doug Simonetto4, María Ayala-Valverde5, Carolina A Ramirez6, Dalia Morales-Arraez7, Wei Zhang8, Steve Qian8, Joseph Ahn4, Seth Buryska4, Heer Mehta2, Muhammad Waleed3, Horia Stefanescu9, Adelina Horhat9..., Andreea Bumbu9, Bashar Agrawal10, Rohit Agrawal10, Joaquín Cabezas11, Berta Cuyàs1, Maria Poca12, German Soriano Pastor12, Shiv K Sarin13, Rakhi Maiwall13, Prasun K Jalal14, María Fátima Higuera-De La Tijera15, Anand Kulkarni16, Nagaraja Rao16, Patricia Guerra Salazar17, Lubomir Skladaný18, Natália Bystrianska18, Veronica Prado19, Ana Clemente-Sanchez20, Diego Rincón20, Tehseen Haider21, Kristina R Chacko21, Gustavo A Romero22, Florencia Pollarsky22, Juan Carlos Restrepo23, Luis G Toro2, Pamela Yaquich25, Manuel Mendizabal26, Maria Laura Garrido27, Sebastian Marciano28, Melisa Dirchwolf29, Victor Vargas30, Cesar Jimenez30, Guadalupe García-Tsao31, Guillermo Ortiz31, Juan G Abraldes32, Patrick Kamath4, Vijay Shah4, Ramon Bataller33, Juan Pablo Arab34,24Ver más
1 Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile
2 University of Kansas Medical Center, KS, USA, Kansas, Estados Unidos (EEUU)
3 Division of Gastroenterology and Hepatology, Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA, Sioux Falls, Estados Unidos (EEUU)
4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
5 Hospital El Pino, Santiago, Chile
6 Department of Anesthesia, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada
7 Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Estados Unidos (EEUU)
8 Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
9 Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
10 Division of Gastroenterology and Hepatology, University of Illinois, Chicago, Illinois, USA
11 Gastroenterology, Santander, España
12 Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, CIBERehd, Barcelona, Spain
13 Institute of Liver and Biliary Sciences, New Delhi, India
14 Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA
15 Servicio de Gastroenterología, Hospital General de México, Universidad Nacional Autónoma de México, México DF, México
16 Asian Institute of Gastroenterology, Hyderabad, India
17 Instituto de Gastroenterología Boliviano-Japonés, La Paz, Bolivia
18 Division of Hepatology, Gastroenterology and Liver Transplantation, Department of Internal Medicine II, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic
19 Centre Hospitalier de Luxembourg, Luxembourg
20 Liver Unit, Department of Digestive Diseases Hospital General Universitario Gregorio Marañón Madrid, Spain
21 Division of Gastroenterology and Hepatology, Montefiore Medical Center, Bronx, NY, USA
22 Sección Hepatología, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina
23 Hospital Pablo Tobon Uribe, Universidad de Antioquia, Medellín, Colombia
24 Hospitales de San Vicente Fundación, Medellín-Rionegro, Antioquia, Colombia
25 Departamento de Gastroenterología, Hospital San Juan de Dios, Santiago, Chile
26 Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Buenos Aires, Argentina
27 Hospital Central San Luis, San Luis, Argentina
28 Liver Unit, Hospital Italiano De Buenos Aires, Buenos Aires, Argentina
29 Unidad de Hígado, Hospital Privado de Rosario, Rosario, Argentina
30 Liver Unit, Hospital Vall d'Hebron, Universitat Autonoma Barcelona, CIBEREHD, Barcelona, Spain
31 Section of Digestive Diseases, Yale University School of Medicine/VA-CT Healthcare System, New Haven/West Haven, USA
32 Division of Gastroenterology, Liver Unit, University of Alberta, Edmonton, Canada
33 Liver Unit, Hospital Clinic, Barcelona, Spain
34 Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada
Ver más
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

Alcohol-associated hepatitis (AH) is a severe entity with a mortality of up to 30–50% at 1 month. Pentoxifylline combined with steroids has not demonstrated benefits in severe AH. Some studies have suggested that pentoxifylline may be beneficial in the subgroup of patients with acute kidney injury (AKI) and AH. However, there is no solid evidence of its benefit in mortality in this setting. This study aimed to determine the benefit of the use of pentoxifylline in patients with severe AH and AKI.

Materials and Methods

Global retrospective cohort study, including patients with severe AH and AKI at admission (2009–2019). We used competing-risk models with liver transplantation as a competing risk to assess the potential effect of pentoxifylline.

Results

We included 655 patients with severe AH and AKI (30 centers from 10 countries). Median age was 48±11.6 years, 26.2% were females, and 52.5% were Caucasian. Around 68.7% of the patients had a prior history of cirrhosis, and 6.6% underwent liver transplantation. The MELD score on admission was 34 [15–74]. 43.2% of the patients used corticosteroids, while only 6.9% used pentoxifylline during hospitalization. In the univariate analysis, the variables independently associated with mortality were the female sex (sHR 0.740; 95%IC:0.577–0.948; p=0.018), MELD (sHR 1.034; 95%IC: 1.020–1048; p<0.001), MELD 3.0 (sHR 1.034,95%IC:1.018–1.049, p<0.001), Maddrey's discriminant function (sHR 1.005, 95%IC:1.003–1.008, p<0.001), serum albumin at admission (sHR 0.756; 95%IC:0.642–0.890; p=0.001), bilirubin at admission (sHR 1.011; 95%IC:1.003–1.019, p=0.006), serum creatinine (sHR 1.083; 95%IC:1.028–1.140, p=0.002) and pentoxifylline use (sHR 1.531, 95%IC:1.107–2.119; p=0.010)(Table). In the multivariate-adjusted model, the use of pentoxifylline was associated with increased mortality (sHR 1.620, 95%IC:1.190–2.204; p=0.002).

Conclusions

The use of pentoxifylline has no benefit in terms of mortality and could decrease survival in patients with AH and AKI.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos